Martin Dietrich, MD, PhD

Articles

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

June 27th 2024

Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.

Key Takeaways for Concurrent Biomarker Testing in NSCLC

June 18th 2024

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.

Overcoming Barriers to NSCLC Biomarker Testing

June 11th 2024

Key opinion leaders delve into the challenges posed by payers, costs, out-of-pocket maximums, and the need for letters of medical necessity, while also addressing additional sources of resistance encountered in clinical practice.

Challenges of NSCLC Biomarker Testing in Clinical Practice

June 11th 2024

Zofia Piotrowska, MD, MHS, shares insights into the challenges and advantages of diagnostic testing practices at Massachusetts General Hospital, including the benefits of on-site testing, the need for less streamlined consent forms, and areas for improvement to expedite the diagnostic testing ordering process.

Reflex Testing for Patients with Suspected Lung Cancer

June 4th 2024

Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.

Biomarker Testing in Early-Stage NSCLC

June 4th 2024

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.

Key Takeaways in HER2-Mutated NSCLC

May 29th 2024

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Treatment Considerations in HER2-Mutated NSCLC

May 29th 2024

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer

May 28th 2024

The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.

NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

May 28th 2024

Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.

Challenges and Unmet Needs in HER2-Mutated NSCLC

May 22nd 2024

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

Adverse Events Associated With TKIs in HER2-Mutated NSCLC

May 22nd 2024

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Concurrent NSCLC Biomarker Testing at Diagnosis

May 21st 2024

Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.

Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing

May 21st 2024

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the crucial role of molecular testing in disease diagnosis, focusing on the significance of rapid turnaround times and the ability of liquid biopsies to address time-sensitive diagnostic needs.

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15th 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15th 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

The Potential Role of TKIs in HER2-Mutated NSCLC

May 8th 2024

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC

May 8th 2024

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.